Time point | NRI (n = 70) |
No (%) | |
6 Months in CHARM | 32 (46) |
1 Year in CHARM | 29 (41) |
24 Weeks in ADHERE | 25 (36) |
36 Weeks in ADHERE | 26 (37) |
48 Weeks in ADHERE | 23 (33) |
60 Weeks in ADHERE† | 22 (31) |
*Includes all adalimumab-treated patients (every other week and weekly groups combined, N = 70) with fistulas at baseline of the Crohn’s Trial of the Fully Human Antibody Adalimumab for Remission Maintenance (CHARM). Fistula efficacy defined as complete healing/closure of draining fistulas at time point since baseline of CHARM. †60 weeks in the Additional Long-Term Dosing with HUMIRA to Evaluate Sustained Remission and Efficacy in Crohn’s disease (ADHERE) study represents approximately 2 years of adalimumab therapy. NRI, non-responder imputation.